viewAusCann Group Holdings Ltd

AusCann Group’s MacLeman buys shares on-market

This purchase follows recent buying from the company’s board’s chairman.

man with briefcase running up ascending share price arrow
MacLeman is serving as interim CEO and will be replaced by Ido Kanyon in May 2019

AusCann Group Holdings Ltd’s (ASX:AC8) interim CEO and director Paul MacLeman has purchased 30,268 shares priced at 33 cents each via on-market trades.

MacLeman is an experienced pharmaceutical executive and was appointed to the company’s board in September 2018.

This is MacLeman’s first purchase of company shares.

READ: AusCann Group chairman buys $58,238 worth of shares on-market

In late February 2019, AusCann appointed global pharmaceutical business executive Ido Kanyon as its CEO commencing 22 May 2019.

Kanyon brings more than 15 years’ senior executive experience in the pharmaceutical industry most recently at multi-billion dollar Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Quick facts: AusCann Group Holdings Ltd

Price: 0.15 AUD

Market: ASX
Market Cap: $47.56 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AusCann Group Holdings Ltd named herein, including the promotion by the Company of AusCann Group Holdings Ltd in any Content on the Site, the...


Auscann targeting pain management with Australian cannabinoid products

Elaine Darby, managing director of Auscann Group Holdings Ltd (ASX:AC8), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney. Auscann is continuing to make steady progress towards releasing its first medicinal cannabis products during the financial year 2019....

on 6/9/18

2 min read